Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 77Prostatic Neoplasms 56Carcinoma, Non-Small-Cell Lung 50Breast Neoplasms 49Esophageal Neoplasms 47Rectal Neoplasms 41Lung Neoplasms 40Squamous Cell Carcinoma of Head and Neck 32Gliosarcoma 31Head and Neck Neoplasms 30Brain Neoplasms 30Pancreatic Neoplasms 29Uterine Cervical Neoplasms 27Neoplasm Metastasis 23Glioma 23Neoplasms 22Oropharyngeal Neoplasms 20Sarcoma 19Esophageal Squamous Cell Carcinoma 19Melanoma 18Astrocytoma 17Adenocarcinoma Of Esophagus 15Stomach Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Carcinoma, Squamous Cell 12Urinary Bladder Neoplasms 11Lymphoma, Follicular 11Central Nervous System Neoplasms 11Carcinoma 11Burkitt Lymphoma 10

Interventions

Chemoradiotherapy 2Radiation 1Paclitaxel 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Cetuximab 1Carboplatin 1Adjuvants, Immunologic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Resectable Esophageal Cancer × Radiation × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡